MRTX1719, an MTA-cooperative PRMT5 Inhibitor, Induces Cell Cycle Arrest and Synergizes With Oxaliplatin and Gemcitabine for Enhanced Anticancer Effects
MRTX1719 reduces PRMT5 activity, leading to cell cycle arrest by increasing the proportion of cells in the G<sub>0</sub>/G<sub>1</sub> phase. Moreover, MRTX1719 exhibits synergistic anticancer effects with oxaliplatin and gemcitabine in MTAP-deficient cancer cells.
Authors
- Fumito Saijo (ORCID: https://orcid.org/0000-0002-2849-4159)
- Koji Okamoto (ORCID: https://orcid.org/0000-0001-7587-0164)
- Hirofumi Imoto (ORCID: https://orcid.org/0000-0003-2037-4643)
- Masamichi Mizuma (ORCID: https://orcid.org/0000-0002-6436-5477)
- Makoto Kawamura (ORCID: https://orcid.org/0000-0001-6117-2736)
- Naoki Tanaka (ORCID: https://orcid.org/0000-0002-3212-3836)
- Norihiko Sugisawa (ORCID: https://orcid.org/0000-0003-1887-7268)
- Akihiro Yamamura (ORCID: https://orcid.org/0000-0003-3602-3231)
- Shinobu Ohnuma (ORCID: https://orcid.org/0000-0002-0205-8957)
- Toshihiro Soeta
- Takashi Kamei (ORCID: https://orcid.org/0000-0003-1282-0463)
- Takahiro Tsuchiya
- Takashi Aizawa
- MICHIAKI UNNO
Institutions
- Tohoku University (JP)
- Miyagi Prefectural Hospital Organization (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2024-12-01
- DOI
- https://doi.org/10.21873/anticanres.17351
- Citations
- 4
- Primary Topic
- Cancer-related gene regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.94